E
bluebird bio, Inc.
BLUE
$4.95
$0.061.23%
E
Sell
3/14/2023Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, valuation index and growth index. Total revenue declined 95.33% from $1.52M to $71, and debt to equity increased from 0.27 to 0.28.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, valuation index and growth index. Total revenue declined 95.33% from $1.52M to $71, and debt to equity increased from 0.27 to 0.28.
D
Sell
9/6/2022Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 9/6/2022 due to an increase in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 9/6/2022 due to an increase in the total return index and volatility index.
D
Sell
8/8/2022Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 8/8/2022 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 24.69% from -$125.3M to -$94.36M, earnings per share increased from -$1.66 to -$1.3575, and EBIT increased 16.27% from -$120.35M to -$100.76M.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 8/8/2022 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 24.69% from -$125.3M to -$94.36M, earnings per share increased from -$1.66 to -$1.3575, and EBIT increased 16.27% from -$120.35M to -$100.76M.
E
Sell
8/2/2022Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 8/2/2022 due to a decline in the volatility index.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 8/2/2022 due to a decline in the volatility index.
D
Sell
7/15/2022Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 7/15/2022 due to an increase in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 7/15/2022 due to an increase in the volatility index and total return index.
E
Sell
6/30/2022Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 6/30/2022 due to a decline in the volatility index.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 6/30/2022 due to a decline in the volatility index.
D
Sell
6/15/2022Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 6/15/2022 due to an increase in the volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 6/15/2022 due to an increase in the volatility index.
E
Sell
5/31/2022Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 5/31/2022 due to a decline in the volatility index.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 5/31/2022 due to a decline in the volatility index.
D
Sell
5/16/2022Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 5/16/2022 due to an increase in the growth index. Earnings per share increased from -$2.1387 to -$1.66, total revenue increased 21.11% from $1.61M to $1.95M, and EBIT increased 10.63% from -$134.67M to -$120.35M.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 5/16/2022 due to an increase in the growth index. Earnings per share increased from -$2.1387 to -$1.66, total revenue increased 21.11% from $1.61M to $1.95M, and EBIT increased 10.63% from -$134.67M to -$120.35M.
E
Sell
3/4/2022Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 3/4/2022 due to a decline in the growth index, solvency index and volatility index. Total revenue declined 273.22% from $22.68M to -$39.28M, debt to equity increased from 0.03 to 0.06, and the quick ratio declined from 2.99 to 2.02.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 3/4/2022 due to a decline in the growth index, solvency index and volatility index. Total revenue declined 273.22% from $22.68M to -$39.28M, debt to equity increased from 0.03 to 0.06, and the quick ratio declined from 2.99 to 2.02.
D
Sell
11/23/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 11/23/2021.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 11/23/2021.
E
Sell
11/8/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and solvency index. The quick ratio declined from 3.45 to 2.99.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and solvency index. The quick ratio declined from 3.45 to 2.99.
D
Sell
11/5/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 11/5/2021 due to an increase in the volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 11/5/2021 due to an increase in the volatility index.
E
Sell
10/20/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 10/20/2021 due to a decline in the volatility index, total return index and valuation index.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 10/20/2021 due to a decline in the volatility index, total return index and valuation index.
D
Sell
10/1/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 10/1/2021 due to an increase in the volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 10/1/2021 due to an increase in the volatility index.
E
Sell
9/15/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 9/15/2021 due to a decline in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D- on 9/15/2021 due to a decline in the volatility index and total return index.
D
Sell
8/30/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 8/30/2021 due to an increase in the volatility index and valuation index.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 8/30/2021 due to an increase in the volatility index and valuation index.
E
Sell
8/10/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to E+ from D on 8/10/2021 due to a substantial decline in the growth index and solvency index. Debt to equity increased from 0.02 to 0.03, total revenue declined 41.6% from $12.79M to $7.47M, and the quick ratio declined from 5.02 to 3.45.
bluebird bio, Inc. (BLUE) was downgraded to E+ from D on 8/10/2021 due to a substantial decline in the growth index and solvency index. Debt to equity increased from 0.02 to 0.03, total revenue declined 41.6% from $12.79M to $7.47M, and the quick ratio declined from 5.02 to 3.45.
D
Sell
6/7/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 6/7/2021 due to an increase in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 6/7/2021 due to an increase in the volatility index and total return index.
D
Sell
5/21/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 5/21/2021 due to a decline in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 5/21/2021 due to a decline in the volatility index and total return index.
D
Sell
5/6/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 5/6/2021 due to an increase in the growth index. Total revenue increased 19.48% from $10.71M to $12.79M.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 5/6/2021 due to an increase in the growth index. Total revenue increased 19.48% from $10.71M to $12.79M.
D
Sell
4/21/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 4/21/2021 due to a decline in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 4/21/2021 due to a decline in the volatility index and total return index.
D
Sell
4/6/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 4/6/2021 due to an increase in the volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 4/6/2021 due to an increase in the volatility index.
D
Sell
3/18/2021Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 3/18/2021 due to a decline in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 3/18/2021 due to a decline in the volatility index and total return index.
D
Sell
2/24/2021Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 2/24/2021 due to a noticeable increase in the growth index and valuation index.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 2/24/2021 due to a noticeable increase in the growth index and valuation index.
D
Sell
11/12/2020Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 11/12/2020 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.3555 to -$2.9395, EBIT declined 590.3% from -$27.6M to -$190.52M, and operating cash flow declined 474.36% from $39.74M to -$148.78M.
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 11/12/2020 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.3555 to -$2.9395, EBIT declined 590.3% from -$27.6M to -$190.52M, and operating cash flow declined 474.36% from $39.74M to -$148.78M.
D
Sell
5/1/2020Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 05/01/2020.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 05/01/2020.
D
Sell
3/24/2020Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 3/24/2020 due to a decline in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 3/24/2020 due to a decline in the total return index and volatility index.
D
Sell
3/9/2020Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 3/9/2020 due to an increase in the valuation index and volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 3/9/2020 due to an increase in the valuation index and volatility index.
D
Sell
2/21/2020Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 2/21/2020 due to a major decline in the total return index, solvency index and efficiency index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 6.09 to 5.01, and total capital declined 11.49% from $1.67B to $1.48B.
bluebird bio, Inc. (BLUE) was downgraded to D- from D on 2/21/2020 due to a major decline in the total return index, solvency index and efficiency index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 6.09 to 5.01, and total capital declined 11.49% from $1.67B to $1.48B.
D
Sell
5/30/2018Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D from D+ on 5/30/2018 due to a large decline in the total return index, solvency index and efficiency index. The quick ratio declined from 13.57 to 10.54, and total capital declined 3% from $1.78B to $1.73B.
bluebird bio, Inc. (BLUE) was downgraded to D from D+ on 5/30/2018 due to a large decline in the total return index, solvency index and efficiency index. The quick ratio declined from 13.57 to 10.54, and total capital declined 3% from $1.78B to $1.73B.
D
Sell
4/10/2018Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 4/10/2018 due to a significant decline in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 4/10/2018 due to a significant decline in the total return index and volatility index.
C
Hold
3/26/2018Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 3/26/2018 due to a noticeable increase in the total return index, solvency index and efficiency index. The quick ratio increased from 9.6 to 13.57, and total capital increased 37.25% from $1.3B to $1.78B.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 3/26/2018 due to a noticeable increase in the total return index, solvency index and efficiency index. The quick ratio increased from 9.6 to 13.57, and total capital increased 37.25% from $1.3B to $1.78B.
D
Sell
1/5/2018Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 1/5/2018 due to a decline in the total return index and valuation index.
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 1/5/2018 due to a decline in the total return index and valuation index.
C
Hold
12/11/2017Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 12/11/2017 due to an increase in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 12/11/2017 due to an increase in the total return index and volatility index.
D
Sell
11/13/2017Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 11/13/2017 due to a noticeable decline in the total return index, solvency index and efficiency index. The quick ratio declined from 14.13 to 9.6, net income declined 11.15% from -$70.9M to -$78.81M, and total capital declined 4.25% from $1.35B to $1.3B.
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 11/13/2017 due to a noticeable decline in the total return index, solvency index and efficiency index. The quick ratio declined from 14.13 to 9.6, net income declined 11.15% from -$70.9M to -$78.81M, and total capital declined 4.25% from $1.35B to $1.3B.
C
Hold
10/30/2017Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 10/30/2017 due to a major increase in the total return index, growth index and solvency index. Total revenue increased 144.67% from $6.83M to $16.72M, the quick ratio increased from 9.02 to 14.13, and operating cash flow increased 28.91% from -$75.3M to -$53.53M.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 10/30/2017 due to a major increase in the total return index, growth index and solvency index. Total revenue increased 144.67% from $6.83M to $16.72M, the quick ratio increased from 9.02 to 14.13, and operating cash flow increased 28.91% from -$75.3M to -$53.53M.
D
Sell
4/11/2017Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 4/11/2017 due to an increase in the volatility index and valuation index.
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 4/11/2017 due to an increase in the volatility index and valuation index.
D
Sell
3/16/2017Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D from D+ on 3/16/2017 due to a decline in the valuation index and total return index.
bluebird bio, Inc. (BLUE) was downgraded to D from D+ on 3/16/2017 due to a decline in the valuation index and total return index.
D
Sell
3/1/2017Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 3/1/2017 due to a significant increase in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 3/1/2017 due to a significant increase in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
C
Hold
3/1/2016Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 3/1/2016 due to an increase in the growth index. Operating cash flow increased 13.82% from -$29.07M to -$33.09M, total revenue increased 11.18% from $1.32M to $1.47M, and earnings per share increased from -$1.1797 to -$1.2876.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 3/1/2016 due to an increase in the growth index. Operating cash flow increased 13.82% from -$29.07M to -$33.09M, total revenue increased 11.18% from $1.32M to $1.47M, and earnings per share increased from -$1.1797 to -$1.2876.
D
Sell
1/29/2016Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 1/29/2016 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 28.94 to 21.08.
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 1/29/2016 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 28.94 to 21.08.
C
Hold
10/5/2015Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 10/5/2015 due to an increase in the valuation index and total return index.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 10/5/2015 due to an increase in the valuation index and total return index.
D
Sell
8/10/2015Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 8/10/2015 due to a noticeable decline in the growth index and total return index. Operating cash flow declined 49.84% from -$24.16M to -$12.12M, and total revenue declined 22.13% from $6.34M to $4.94M.
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 8/10/2015 due to a noticeable decline in the growth index and total return index. Operating cash flow declined 49.84% from -$24.16M to -$12.12M, and total revenue declined 22.13% from $6.34M to $4.94M.
C
Hold
1/5/2015Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 1/5/2015 due to an increase in the total return index.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 1/5/2015 due to an increase in the total return index.
D
Sell
12/9/2014Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 12/9/2014 due to a decline in the growth index and efficiency index.
bluebird bio, Inc. (BLUE) was downgraded to D+ from C- on 12/9/2014 due to a decline in the growth index and efficiency index.
C
Hold
11/4/2014Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 11/4/2014 due to an increase in the total return index.
bluebird bio, Inc. (BLUE) was upgraded to C- from D+ on 11/4/2014 due to an increase in the total return index.
D
Sell
10/17/2014Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 10/17/2014 due to an increase in the valuation index.
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 10/17/2014 due to an increase in the valuation index.
D
Sell
10/1/2014Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D from C- on 10/1/2014 due to a decline in the total return index and volatility index.
bluebird bio, Inc. (BLUE) was downgraded to D from C- on 10/1/2014 due to a decline in the total return index and volatility index.
C
Hold
9/16/2014Upgraded
bluebird bio, Inc. (BLUE) was upgraded to C- from D on 9/16/2014 due to an increase in the volatility index.
bluebird bio, Inc. (BLUE) was upgraded to C- from D on 9/16/2014 due to an increase in the volatility index.
D
Sell
9/15/2014Downgrade
bluebird bio, Inc. (BLUE) was downgraded to D from D+ on 9/15/2014 due to a decline in the valuation index.
bluebird bio, Inc. (BLUE) was downgraded to D from D+ on 9/15/2014 due to a decline in the valuation index.
D
Sell
8/14/2014Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 8/14/2014 due to a noticeable increase in the total return index, volatility index and valuation index.
bluebird bio, Inc. (BLUE) was upgraded to D+ from D on 8/14/2014 due to a noticeable increase in the total return index, volatility index and valuation index.
D
Sell
7/1/2014Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 7/1/2014 due to a major increase in the volatility index and total return index.
bluebird bio, Inc. (BLUE) was upgraded to D from D- on 7/1/2014 due to a major increase in the volatility index and total return index.
D
Sell
3/3/2014Upgraded
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 3/3/2014 due to an increase in solvency.
bluebird bio, Inc. (BLUE) was upgraded to D- from E+ on 3/3/2014 due to an increase in solvency.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
